Binder DesignBinder Design

Design a PD-L1 Binder in Your Browser: A Weekend Project

A complete walkthrough of designing a PD-L1 binder using SciRouter's Binder Design Lab — from picking the target to downloading top candidates.

SciRouter Team
April 11, 2026
12 min read

If you want one concrete weekend project to understand modern protein design, try designing a PD-L1 binder. It is a real target, the biology is well studied, the PDB has everything you need, and the whole campaign fits inside two days of evenings plus a fifteen-minute run on a hosted GPU. This tutorial walks through the plan.

Why PD-L1?

PD-L1 is a membrane protein on many cells. When it binds PD-1 on a T cell, it sends an inhibitory signal that tells the T cell to stand down. Tumors exploit this by expressing PD-L1 to avoid immune attack. Checkpoint-inhibitor antibodies like pembrolizumab and atezolizumab block the PD-1 to PD-L1 interaction and have become standard of care in several oncology indications.

For protein design practice, PD-L1 has three things going for it:

  • A clear, well-studied interface. The PD-1 to PD-L1 contact surface is characterized in multiple crystal structures. You do not need to guess where the binding site lives.
  • Good benchmarks. Published de novo binders and approved monoclonal antibodies give you baselines to compare against.
  • Practical size. PD-L1 is small enough that structure prediction and generation are fast. A full campaign finishes in minutes, not hours.
Note
This is a learning project. Nothing you design here is a drug. If you want to pursue a therapeutic binder, you will need specificity testing, off-target screening, pharmacokinetics work, and regulatory strategy. This post is about the first design step only.

Step 1: Load the target structure

Open the Binder Design studio and enter PDB ID 5C3T. This structure shows PD-1 and PD-L1 in complex, which is useful because you can see exactly which residues make contact.

The studio will render both chains, color-code the interface, and let you click residues to add them to the hotspot list.

Step 2: Pick hotspot residues

The residues on PD-L1 that make the strongest contacts with PD-1 include:

  • Tyr56 — aromatic anchor in the center of the interface
  • Glu58 — hydrogen bond donor on the edge
  • Asp61 — salt bridge partner
  • Arg113 — positive charge near the rim
  • Tyr123 — second aromatic anchor

Pick three or four of these as your hotspots. You do not need all of them. In fact using too many hotspots over-constrains the generator and can reduce diversity.

Step 3: Run BindCraft

Click Run Campaign in the studio, or call the API directly. Here is the minimal request:

PD-L1 campaign via Python SDK
from scirouter import SciRouter

client = SciRouter(api_key="sk-sci-YOUR_API_KEY")

result = client.labs.binder.discover(
    target_pdb_id="5C3T",
    target_chain="A",             # chain A is PD-L1 in 5C3T
    hotspot_residues=[56, 58, 61, 123],
    num_designs=60,
    min_length=65,
    max_length=95,
)

top = sorted(result.ranked_candidates, key=lambda d: -d.score)[:10]
for i, design in enumerate(top):
    print(f"#{i+1}  score={design.score:.3f}  len={len(design.sequence)}")
    print(f"    seq={design.sequence}")

Under the hood this triggers the same BindCraft pipeline described in our BindCraft tutorial: BoltzGen generates backbones, Boltz-2 validates interfaces, and ProteinMPNN designs sequences. The run takes about 10 minutes end to end for 60 designs.

Step 4: Read the output

The top candidates will usually cluster into a few backbone topologies. Some will be three-helix bundles. Some will be small beta-sheet scaffolds. Some will be mixed alpha-beta. All three are worth exploring.

For each candidate, pay attention to:

  • BindCraft score. Above 0.7 is promising. Below 0.5 is probably not worth ordering.
  • Interface coverage. How many of your hotspots does the design actually touch in the predicted pose? Good designs hit at least three of four.
  • Self-consistency. Does the predicted structure of the designed sequence match the generated backbone? This is a proxy for whether the sequence will actually fold.

Step 5: Pick your panel

For a first campaign, pick 10 candidates split across:

  • The top 5 by overall BindCraft score.
  • 2 backbone topologies that are structurally different from the top 5 but still scored above 0.6.
  • 1 “aggressive” pick with a slightly lower score but unusually good interface coverage.
  • 1 negative control: a scrambled sequence that should not fold into a binder.
  • 1 positive control: a published nanobody or small protein binder against PD-L1 from the literature.

Step 6: Wet-lab validation (optional)

If you have access to a molecular biology setup, the cheapest path to first data is:

  • Order the 10 sequences as gene fragments (Twist, IDT, or GenScript).
  • Clone into a standard bacterial expression vector with a 6xHis tag.
  • Express in E. coli, purify by nickel affinity, and measure concentration.
  • Test binding against a commercial PD-L1 extracellular domain by biolayer interferometry, surface plasmon resonance, or fluorescence polarization.

Most well-resourced academic labs can complete this workflow in three weeks. Even one hit is a meaningful result and teaches you a lot about what worked in your design choices.

What you will learn

The goal of this project is not to beat pembrolizumab. It is to understand:

  • How to read a PDB interface and choose hotspots.
  • How generative models score and rank candidates.
  • What a realistic hit rate feels like in practice.
  • Why diversity in the candidate pool matters more than any single top-ranked design.
  • How to plan a wet-lab validation panel without blowing your budget.

Once you have done it once, you can apply the same recipe to any target you care about. For a more general take on what this unlocks, see our weekend project guide.

Bottom line

Designing a PD-L1 binder used to be a multi-year research program. In 2026 it is a weekend computational project plus a cheap expression campaign. The tools are there. The biology is understood. The only thing left is for you to pick a target and actually try.

Open the Binder Design studio →

Frequently Asked Questions

Why is PD-L1 a good first target?

PD-L1 has a well-defined interface with PD-1, plenty of published binders and antibodies to compare against, and several high-quality crystal structures in the PDB. The binding site is small enough that even modest-quality generative pipelines can find candidates, which makes it a great teaching target.

Do I need a wet lab to learn from this project?

No. You can get a lot out of the computational part alone. You will learn how to pick hotspots, how to read interface confidence scores, and how to compare candidates. If you do want to test in a lab, ordering 8 to 12 gene fragments and running a simple binding assay is within reach of most academic groups.

What is the difference between PD-1 and PD-L1?

PD-1 is a receptor on T cells. PD-L1 is its ligand, expressed on many cell types including many tumor cells. Their interaction dampens T cell activity. Checkpoint inhibitor drugs block this interaction to release the brakes on the immune response.

Which PDB structure should I use?

PDB ID 5C3T is a good starting point because it shows the PD-1 to PD-L1 interface in detail. 4Z18 is another commonly used structure. You can upload either to the Binder Design studio and pick hotspots directly from the rendered surface.

How many candidates should I order?

For a first weekend project, 8 to 12 is a reasonable sweet spot. That is enough to cover a few different backbone topologies and give yourself a realistic shot at a hit, without exploding your gene-synthesis budget.

Can this workflow replace monoclonal antibodies?

Not for clinical use, no. Monoclonal antibodies have decades of regulatory history, manufacturing processes, and clinical data behind them. De novo binders are promising research tools and potential scaffolds for new therapeutics, but they are earlier in the maturity curve.

Try this yourself

500 free credits. No credit card required.